ASTCT

ASTCT is seeking passionate individuals to volunteer on a SIG or committee. This member-exclusive opportunity allows you to work with colleagues across the globe and make a direct impact on our organization. 🤝

Applications are due Friday, Nov. 7: https://ow.ly/qeKW50X5Pic

Whether you're a clinician, researcher, nurse or trainee, ASTCT membership gives you access to specialized educational content, CE opportunities and significant savings on meetings, including the 2026 Tandem Meetings.

Join or renew now for access to benefits through 2026: https://ow.ly/3ZUn50X594m

Applications for the 2026 Leadership Course are now open! Receive 1:1 training and development to help you in your new or future leadership role from current program directors in the HCT and cellular therapy field. Apply by Nov. 24: https://ow.ly/Owvg50Xeg4e

💡 Present your science on one of the biggest stages in hematopoietic cell transplantation, gene and cellular therapy. Submit an abstract by Oct. 9 and help shape the scientific program at the 2026 Tandem Meetings: ow.ly/wyrJ50WMqJY #Tandem26

Providers and Patients Are Encouraged to Remain Hypervigilant for Years After Transplant Regarding Potential Manifestations of Chronic GVHD - Orion Brand Studio Chronic graft-versus-host disease (GVHD) occurs in up to 70% of patients who have undergone an allogeneic hematopoietic stem cell transplant and is the main cause of late, non-relapse mortality.1 It [...

Providers and Patients Are Encouraged to Remain Hypervigilant for Years After Transplant Regarding Potential Manifestations of Chronic GVHD — www.orionbrandstudio.com/supported-co...

Nominations for the Society's premier awards close soon! These awards are given in recognition of individuals who have dedicated their time, knowledge & expertise to improve the work of the #HCT & cell therapy community. Nominate someone now: ow.ly/rNoR50WRuCk

ASTCT & CIBMTR are now accepting abstract submissions for #Tandem26! Share your HCT, cell therapy & gene therapy research with colleagues in the field. Submissions are due Oct. 9 & there will not be any deadline extensions. Learn more: ow.ly/wyrJ50WMqJY

Did you know ASTCT webinars are free to register for? We have a full calendar of upcoming webinars related to #HCT, #CART, #pharmacy, #Tandem25 sessions and more. View all webinars and register to attend one this month: www.astct.org/Meetings/Mee... #OncSky #HemeSky #MedSky

ASTCT's New Investigator Awards (NIAs) are designed to encourage clinical and/or laboratory research by young investigators in the field of hematopoietic cell, cell therapy and/or gene therapy. Apply now or share this opportunity: ow.ly/Te6T50WuV9O

This 'Transplantation and Cellular Therapy' study identified advanced age, high comorbidities, UCB, & PTCy haploidentical HCT as factors significantly benefiting survival with LTV. The heterogeneity of LTV survival benefits showed the importance of personalized clinical decisions. ow.ly/LVe650WsP3E

🌟 For the first time, ASTCT is accepting abstracts to the Gene Therapy Summit! Be among the first researchers to share your gene therapy findings at this landmark meeting. Submit your abstract by Aug. 10: ow.ly/ocbb50Ws2MZ

Join ASTCT as a member with extended membership now through July 15 to be entered to win complimentary registration to your choice of the 2025 Clinical Education Course (CEC) or the 2026 Fundamentals of HCT Training Course! Learn more & join today: ow.ly/t7mO50Wkytj

Join ASTCT as a member with extended membership now through July 15 to be entered to win complimentary registration to your choice of the 2025 Clinical Education Course (CEC) or the 2026 Fundamentals of HCT Training Course! Learn more & join today: ow.ly/z5KT50Wkytl

ASTCT & CancerNetwork organized an X Space hosted by Rahul Banerjee; Taha Al-Juhaishi & Muhammad Salman Faisal to discuss key presentations and abstracts of interest at the ⁠2025 ASCO Annual Meeting⁠. Listen now to catch up on what was discussed: ow.ly/4KJt50Wasku

Great @astct.bsky.social & @sitcancer.bsky.social Solid Tumor Summit in Chicago yesterday. Important discussions with multiple stakeholders including academia industry and community practice to bring novel cellular therapies to patients with solid tumors.

Deadline extended ‼️ The deadline to submit an abstract for the ASTCT + EBMT #RelapseConference25 to June 2. Showcase your relapse post-transplant-related findings this fall in Madrid: ow.ly/7YN850VSX4n

Applications are open for the 2026 International Trainee Observership Program. One international trainee from a low/mid-income country will participate in 4-week-long observership at the @uofcahealth.bsky.social.

📆 Deadline to apply: Friday, June 13
ow.ly/Ih0650VK0vn #MedSky #HCT #celltherapy

ASTCT is excited to unveil our improved practice guidelines app! Features include:
✅ Integration of a GVHD tool to diagnose & score
✅ Filter easily b/n HCT & cell therapy
✅ Built-in calculators for critical risk factors & diagnosis
✅ Easy access to ASTCT practice guidelines

#MedSky #OncSky #HemeSky

You won't want to miss this webinar—on May 1 experts from
@mskcancercenter.bsky.social & @fredhutch.bsky.social
will cover the rising concern of measles outbreaks and their unique risks for our patient populations. Register for free: ow.ly/ptUx50VF25j #MedSky #MedEd

Ide-Cel Displays Potential in Myeloma After Suboptimal Response to Frontline ASCT and Maintenance Alfred L. Garfall, MD, discusses the role of ide-cel in patients with multiple myeloma following suboptimal responses to upfront auto-HCT.

Ide-Cel Displays Potential in Myeloma After Suboptimal Response to Frontline ASCT and Maintenance @pennmedicine.bsky.social @astct.bsky.social #Tandem25
#MultipleMyeloma #MMSM
www.onclive.com/view/ide-cel...

Now is your chance to make an impact among HCT & cell therapy researchers — submit an abstract to the ASTCT + EBMT Relapse Conference! Showcase your relapse post-transplant-related findings this fall in Madrid: ow.ly/O50I50Vsuia

ASTCT's journal, 'Transplantation and Cellular Therapy,' recently released a new supplement dedicated to the latest research, challenges & innovations in Tumor-Infiltrating Lymphocyte (TIL) therapy, supported through an educational grant provided by Iovance Biotherapeutics: ow.ly/MviL50VlXTi

The Fundamentals of HCT Training Course provides a broad intro to #HCT & cellular immunotherapy; it incorporates case-based learning to emphasize the application of concepts taught, with a strong focus on pharmacotherapeutic management. Register now or share: ow.ly/j69f50QIyfQ

Impactful work and leadership by @astct.bsky.social to reduce regulatory burden for centers offering #CellTherapy #CARTcells

🧬 #Tandem25 Recap: This session explored the promise of next-generation sequencing in TID, while also addressing key challenges.

Learn more: ow.ly/MBjM50V6jnE

Improvement in autoimmune diseases after CAR T therapy. Of patients with active autoimmune disease on treatment at time of CAR T, 4 patients had an improvement of their autoimmune disease, 3 stable disease, and 1 worsening. The patients who benefitted had SLE, APS, RA, and CAD.

There’s been much discussion about CAR T for severe autoimmune disease, incl. lupus & MS. What can we learn about how that might work from patients who have both cancer & autoimmune disease and get B-/plasma-cell directed CAR T?

From Jennifer Huang @fredhutch.bsky.social #Tandem25 #OncSky #RheumSky

#tandem25 #bmtsm Perales: recent TCT journal issue dedicated for subspecialty mgmt of cGVHD. Good ref for ophthalmology, pulm, derm, etc.

Congratulations to @sghmd.bsky.social, the 2025 recipient of the Lukas D. Wartman GVHD Achievement Award. This award recognizes Dr. Holtan for her exceptional work and dedication to advancing GVHD patient care. Dr. Lukas D. Wartman personally bestowed the award to Dr. Holtan at #Tandem25.

Fred Hutch at #Tandem25: Catch presentations from Dr. Jennifer Adair, Elizabeth Krantz and Dr. Jennifer Huang on global access to #genetherapy, #cartcelltherapy and more. Details: bit.ly/4jW3ukj

Orca-T’s Display of Decreased NRM, Increased RFS May Contribute to Favorable OS in Hematologic Malignancies Orca-T improved OS vs post-transplant cyclophosphamide in a retrospective analysis of patients with hematologic malignancies.

Orca-T’s Display of Decreased NRM, Increased RFS May Contribute to Favorable OS in Hematologic Malignancies @astct.bsky.social #TANDEM25 #oncology www.onclive.com/view/orca-t-...